Literature DB >> 2457437

Establishment of human mesothelioma cell lines (MS-1, -2) and production of a monoclonal antibody (anti-MS) with diagnostic and therapeutic potential.

S M Hsu1, P L Hsu, X Zhao, C S Kao-Shan, J Whang-Peng.   

Abstract

We have established and characterized two mesothelioma cell lines, MS-1 and MS-2, in four attempts at long-term culture of these cells. Both MS-1 and MS-2 cells consistently express cytokeratin and vimentin, and both have long, slender microvilli. The cells that grew indefinitely (MS-1, MS-2) had a higher DNA index and a higher nucleus:cytoplasm ratio than did those cells that failed to grow (MS-3, MS-4). All mesothelioma cells, both in short- and in long-term culture, responded to phorbol ester induction by displaying morphological differentiation, such as an increase in the number of microvilli. The distribution of vimentin and cytokeratin in the cells, however, remained the same regardless of the growth pattern or the phorbol-ester treatment of the cells. We have used MS-1 cells to produce a monoclonal antibody (anti-MS) that reacts with mesothelioma cells, but rarely with reactive or normal mesothelial cells or with cells of normal tissues. The antibody does not induce the modulation of antigen, and it causes no direct or complement-mediated cytotoxicity of MS-1 or MS-2 cells. If a toxin or an isotope conjugate of the antibody is used, it may be valuable in the near future to test it for use in immunoimaging or immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457437

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.

Authors:  N J Vogelzang; M Goutsou; J M Corson; Y Suzuki; S Graziano; J Aisner; M R Cooper; K M Coughlin; M R Green
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells.

Authors:  S Shetty; A Kumar; S Idell
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

3.  Establishment of a human malignant fibrous mesothelioma cell line and the biological characteristics compared with malignant epithelial mesothelioma cell line.

Authors:  Iwao Ishiwata; Emiko Ishiwata; Takashi Hirano
Journal:  Hum Cell       Date:  2008-08       Impact factor: 4.174

4.  Establishment and characterization of a human malignant mesothelioma cell line (HMMME).

Authors:  Isamu Ishiwata; Chieko Ishiwata; Mitsuru Anzo; Rie Minami; Kazushige Kiguchi; Toshiaki Tachibana; Hiroshi Ishikawa
Journal:  Hum Cell       Date:  2003-12       Impact factor: 4.174

5.  The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells.

Authors:  Torry A Tucker; Candice Dean; Andrey A Komissarov; Kathy Koenig; Andrew P Mazar; Usha Pendurthi; Timothy Allen; Steven Idell
Journal:  Am J Respir Cell Mol Biol       Date:  2009-07-27       Impact factor: 6.914

6.  Regulation of fibrin deposition by malignant mesothelioma.

Authors:  S Idell; S Pueblitz; S Emri; Y Gungen; L Gray; A Kumar; D Holiday; K B Koenig; A R Johnson
Journal:  Am J Pathol       Date:  1995-11       Impact factor: 4.307

7.  Molecular cloning of a cell-surface glycoprotein that can potentially discriminate mesothelium from epithelium: its identification as vascular cell adhesion molecule 1.

Authors:  T Yamada; J Jiping; R Endo; M Gotoh; Y Shimosato; S Hirohashi
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.